Company news

LENZ Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

April 2, 2024

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

April 1, 2024

LENZ Therapeutics and Graphite Bio Announce Merger Agreement

November 14, 2023

Graphite Bio Announces Departure of Chief Financial Officer

June 22, 2023

Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results

March 19, 2023

Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring

February 21, 2023

Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease

January 4, 2023

Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

December 10, 2022

Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference

November 20, 2022

Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results

November 8, 2022

Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition

November 2, 2022

Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention

October 10, 2022

Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results

August 10, 2022

Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

August 10, 2022

Graphite Bio Announces Participation in Jefferies Healthcare Conference

May 31, 2022

Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results

May 11, 2022

Graphite Bio Announces Participation in Upcoming Investor Conferences

May 3, 2022

Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease

May 2, 2022

Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program

May 1, 2022

Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference

March 27, 2022

Graphite Bio Announces Formation of Scientific Advisory Board

March 22, 2022

Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results

March 20, 2022

Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference

March 2, 2022

Graphite Bio Appoints Alethia Young as Chief Financial Officer

March 1, 2022

Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

December 10, 2021

Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease

December 6, 2021

Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease

November 16, 2021

Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results

November 9, 2021

Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition

November 3, 2021

Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit

October 20, 2021

Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention

October 11, 2021

Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention

October 4, 2021

Graphite Bio Announces Participation in Upcoming September Investor Conferences

August 29, 2021

Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results

August 11, 2021

Graphite Bio Announces Pricing of Upsized Initial Public Offering

June 23, 2021

← Newer news releases

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.